WebOct 21, 2024 · CHARLESTON, S.C., Oct. 21, 2024 /PRNewswire/ -- GlycoPath's proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease infection states and track treatment response through a collaboration with Drexel University College of Medicine, Philadelphia, PA. Dr. Mary Ann Comunale identified … WebFeb 15, 2024 · GlycoPath Inc. is the developer of GlycoTyper-based bioanalytical assays using the Company's proprietary platform technology, developed at the Medical University of South Carolina and licensed ...
GlycoPath Inc. Receives Prestigious Grant from the National …
WebMar 10, 2024 · GlycoPath Inc. is a developer of GlycoTyper-based bioanalytical assays using the Company's proprietary platform technology, developed at the Medical University of South Carolina and licensed from the MUSC Foundation for Research Development. WebFeb 16, 2024 · GlycoPath Inc., developer of advanced bioanalytical assays based on its proprietary GlycoTyper ™ immunoaffinity technology, has appointed Kathy Phlegar as CEO. This change comes as the company continues to drive towards commercialization of its proprietary assays. Kathy Phlegar comes from a strong life sciences strategy and … loyal to a fault big sean
GlycoPath Inc. Secures Seed Investment to Further Develop, …
WebApr 2, 2024 · GlycoTyper is a patent-pending technology developed at MUSC and is licensed by GlycoPath Inc. from the MUSC Foundation for Research Development. Richard Drake, Ph.D., Hollings researcher and … WebFeb 15, 2024 · GlycoPath Inc. is the developer of GlycoTyper-based bioanalytical assays using the Company's proprietary platform technology, developed at the Medical University of South Carolina and licensed ... WebOct 21, 2024 · CHARLESTON, S.C., Oct. 21, 2024 /PRNewswire/ -- GlycoPath's proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease infection states and track treatment ... loyal to a fault mod